THE EVALUATION OF THE INFLUENCE OF CETRILEV (LEVOCETIRIZINE) ON THE LATE PHASE OF THE ATOPIC REACTION

Abstract

Relevance. Previously demonstrated inhibitory effect of levocetirizine on the activity of eosinophils during the late phase of the atopic reaction, but the effect of the drug on the second component of the late phase – lymphocytes – is still not specified.
 Objective of the study – to evaluate the effect of levocetirizine (Cetrilev) therapy on the lymphocyte component of the late phase of atopic allergic reaction in humans.
 Materials and methods. A single-center, prospective, comparative clinical study was conducted. Patients of the study group (SG) (n = 31) with chronic atopic dermatitis and rhinitis received a 14-day therapy with levocetirizine, whereas the control group (CG) (n = 22) patients treated with desloratadine. On the 1st, 7th and 14th day, the inhibition of migration of lymphocytes reaction with mitogens and allergens was evaluated.
 Results. SG achieved a significant increase in the rate of inhibition of migration of lymphocytes with konkanavalin and fitohemeagglutinin mitogens and a more pronounced increase in inhibition of migration of lymphocytes with a specific allergen on the 14th day of therapy (p <0,05, Z <Z0,05), whereas in the CG, only a slight increase in the level of these indicators without achieving significant differences was observed (p> 0,05, Z> Z0,05).
 Conclusions. 14-day therapy with levocetirizine (Cetrilev) inhibits the activity of allergen-specific lymphocytes in children and adults with atopic rhinitis and dermatitis with normalization of the total lymphocyte activity, indicating the effect of this drug on the late phase of the atopic reaction.